Research from Around the world
Lupus News
The Lupus Research Alliance is pleased and very encouraged to share a promising scientific breakthrough reported in the New York Times with real potential to revolutionize lupus treatment. Just reported in the prestigious journal Nature, scientists in Dr. Alexander Marson's lab at the University of California, San Francisco have developed an innovative way to engineer genes of the body's immune system to treat immunologic diseases like lupus, rheumatoid arthritis, cancer and HIV.
Levels of certain antibodies are significantly associated with particular clinical characteristics of systemic lupus erythematosus (SLE), and could be used to assess disease activity in patients, a study finds.
The study, “Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity,” was published in the journal Reumatismo.
Neovacs, a French biotech, obtained positive Phase IIb results showing its lupus vaccine could be effective in treating this severe autoimmune disease.
Its lupus vaccine works by stimulating the patient’s immune system to produce antibodies against a protein called IFNα that regulates the immune system and is involved in the disease.
A clinical trial with 149 patients suffering from systemic lupus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.
